GSK plc (GLAXF)
| Market Cap | 101.21B +34.8% |
| Revenue (ttm) | 43.29B +4.0% |
| Net Income | 7.70B +84.9% |
| EPS | 1.88 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.15 |
| Forward PE | 10.07 |
| Dividend | 0.90 (3.47%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 108 |
| Open | 26.00 |
| Previous Close | 24.58 |
| Day's Range | 26.00 - 26.00 |
| 52-Week Range | 17.15 - 31.48 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK Says Bepirovirsen Achieves Phase III Functional Cure Goal In Chronic Hepatitis B
(RTTNews) - Drugmaker GSK plc (GSK) on Tuesday announced positive Phase III trial results for investigational hepatitis B treatment bepirovirsen.
GSK plc Transcript: Study update
Bepirovirsen achieved functional cure in up to 26% of virologically suppressed chronic hepatitis B patients in phase III trials, with an additional 30% reaching partial cure. The therapy demonstrated an acceptable safety profile and is positioned as a first-in-class finite treatment, with regulatory approvals anticipated soon.
GSK plc Slides: Study update
GSK plc has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
GSK Achieves Key Milestones in Hepatitis B Trials with Bepirovirsen
GSK Achieves Key Milestones in Hepatitis B Trials with Bepirovirsen
Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced data for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B. Results from the two Phase 3 tria...
GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
GSK said its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to...
GSK Showcases Oncology Progress at Upcoming ASCO and EHA Meetings
GSK Showcases Oncology Progress at Upcoming ASCO and EHA Meetings
GSK to present new data from portfolio, pipeline at ASCO Annual Meeting
GSK (GSK) will present new data from its expanding oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL and the 31st…
Notable ETF Inflow Detected - FENI, BTI, AER, GSK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
GSK Expands Arexvy Vaccine Eligibility for RSV Protection
GSK Expands Arexvy Vaccine Eligibility for RSV Protection
GSK announces Japan’s MHLW expanded eligible population for Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has expanded the eligible population for Arexvy, to include adults aged 18 to 49 years at increased risk…
GSK: Japan's MHLW Expands Eligible Population For Arexvy
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include adults aged 18 to 49 years at in...
GSK enters into exclusive strategic collaboration with Sino Biopharm
GSK (GSK) announced that it has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBMFF), through its subsidiary Chia Tai Tianqing Pharmaceutical Group, or CTTQ, to accele...
GSK Partners with China National Pharmaceutical for Bepirovirsen Development
GSK Partners with China National Pharmaceutical for Bepirovirsen Development
GSK Launches Final GBP 0.18 Bln Tranche Of GBP 2 Bln Share Buyback
(RTTNews) - GSK plc (GSK, GSK.L, GS71.DE), on Monday announced the commencement of the fifth and final tranche of its 2 billion pounds share buyback program, covering up to about 0.18 billion pounds, ...
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mai...
Halozyme announces global collaboration and license agreement with GSK
Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery ...
GSK partners with Julie Bowen, Ty Burrell to raise meningitis awareness
GSK (GSK) announced new campaign spokespeople, Julie Bowen and Ty Burrell, as part of its Ask2BSure public health campaign to raise awareness and encourage parents to “ask to be sure”…
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
GSK price target lowered to 2,100 GBp from 2,250 GBp at Citi
Citi lowered the firm’s price target on GSK (GSK) to 2,100 GBp from 2,250 GBp and keeps a Neutral rating on the shares.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely need...
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40